Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Introduction to Alpelisib Film-Coated Tablet 200mg
Alpelisib Film-Coated Tablet 200mg, marketed as Pivikto, is a targeted therapy prescribed for specific types of breast cancer. It is effective in treating hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with PIK3CA mutations, including advanced stages and metastatic disease when combined with hormonal anticancer therapies.
Uses of Alpelisib Film-Coated Tablet 200mg
Alpelisib Film-Coated Tablet 200mg is used for:
Treatment of hormone receptor (HR)-positive, HER2-negative breast cancer with PIK3CA mutations.
Administered alongside hormonal anticancer therapies to enhance treatment outcomes.
Benefits of Alpelisib Film-Coated Tablet 200mg
Delays disease progression and improves survival rates in advanced breast cancer patients.
Targets specific genetic mutations driving cancer growth, providing personalized treatment.
Offers a convenient oral formulation to be taken with food, ensuring patient adherence and comfort during treatment.
Mechanism of Action of Alpelisib Film-Coated Tablet 200mg
Alpelisib Film-Coated Tablet 200mg inhibits PI3K-alpha, a key enzyme in the PI3K/AKT/mTOR signaling pathway. By selectively targeting PIK3CA mutations in cancer cells, it suppresses cell growth and promotes apoptosis, thereby halting tumor progression.